Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Characterization of a novel, trastuzumab resistant human breast cancer cell line.

Barok M, Balazs M, Lazar V, Rakosy Z, Toth E, Treszl A, Vereb G, Colbern GT, Park JW, Szollosi J.

Front Biosci (Elite Ed). 2010 Jan 1;2:627-40.

PMID:
20036907
[PubMed - indexed for MEDLINE]
2.

Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1.

Rennstam K, Jönsson G, Tanner M, Bendahl PO, Staaf J, Kapanen AI, Karhu R, Baldetorp B, Borg A, Isola J.

Cancer Genet Cytogenet. 2007 Jan 15;172(2):95-106.

PMID:
17213017
[PubMed - indexed for MEDLINE]
3.

Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.

Hamel S, Bouchard A, Ferrario C, Hassan S, Aguilar-Mahecha A, Buchanan M, Quenneville L, Miller W, Basik M.

Breast Cancer Res Treat. 2010 Feb;120(1):47-57. doi: 10.1007/s10549-009-0364-7. Epub 2009 Mar 20.

PMID:
19301121
[PubMed - indexed for MEDLINE]
5.

Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.

Luistro LL, Rosinski JA, Bian H, Bishayee S, Rameshwar P, Ponzio NM, Ritland SR.

Int J Oncol. 2012 Aug;41(2):639-51. doi: 10.3892/ijo.2012.1463. Epub 2012 May 8.

PMID:
22580986
[PubMed - indexed for MEDLINE]
6.

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.

Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, Menendez JA.

Oncotarget. 2012 Dec;3(12):1600-14.

PMID:
23307622
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).

Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA.

Int J Oncol. 2010 Sep;37(3):669-78.

PMID:
20664936
[PubMed - indexed for MEDLINE]
8.

Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.

Belkhiri A, Dar AA, Peng DF, Razvi MH, Rinehart C, Arteaga CL, El-Rifai W.

Clin Cancer Res. 2008 Jul 15;14(14):4564-71. doi: 10.1158/1078-0432.CCR-08-0121. Epub 2008 Jun 25.

PMID:
18579663
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.

Shen G, Huang H, Zhang A, Zhao T, Hu S, Cheng L, Liu J, Xiao W, Ling B, Wu Q, Song L, Wei W.

Cancer Immunol Immunother. 2011 Mar;60(3):339-48. doi: 10.1007/s00262-010-0937-7. Epub 2010 Nov 18.

PMID:
21086124
[PubMed - indexed for MEDLINE]
10.

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.

Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.

Breast Cancer Res Treat. 2010 Aug;122(3):685-97. doi: 10.1007/s10549-009-0592-x. Epub 2009 Oct 27.

PMID:
19859802
[PubMed - indexed for MEDLINE]
11.

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.

du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):904-16.

PMID:
16467105
[PubMed - indexed for MEDLINE]
Free Article
12.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.

PMID:
21153051
[PubMed - indexed for MEDLINE]
13.

ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.

Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, Birnbaum D.

Oncogene. 2007 Nov 1;26(50):7163-9. Epub 2007 May 21.

PMID:
17525746
[PubMed - indexed for MEDLINE]
14.

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M; Trastuzumab Response Biomarker Group.

Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430.

PMID:
20661914
[PubMed - indexed for MEDLINE]
Free Article
15.

Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.

Immunol Lett. 2006 Apr 15;104(1-2):146-55. Epub 2005 Dec 12.

PMID:
16384610
[PubMed - indexed for MEDLINE]
16.

Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.

Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ.

Mod Pathol. 2010 Jul;23(7):1029-39. doi: 10.1038/modpathol.2010.84. Epub 2010 May 14.

PMID:
20473280
[PubMed - indexed for MEDLINE]
Free Article
17.

Her2-positive breast cancer: herceptin and beyond.

Dean-Colomb W, Esteva FJ.

Eur J Cancer. 2008 Dec;44(18):2806-12. doi: 10.1016/j.ejca.2008.09.013. Epub 2008 Nov 18. Review.

PMID:
19022660
[PubMed - indexed for MEDLINE]
18.

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

Barok M, Tanner M, Köninki K, Isola J.

Cancer Lett. 2011 Jul 28;306(2):171-9. doi: 10.1016/j.canlet.2011.03.002. Epub 2011 Apr 1.

PMID:
21458915
[PubMed - indexed for MEDLINE]
19.

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.

Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szöllösi J.

Mol Cancer Ther. 2007 Jul;6(7):2065-72.

PMID:
17620435
[PubMed - indexed for MEDLINE]
Free Article
20.

Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.

Barok M, Balázs M, Nagy P, Rákosy Z, Treszl A, Tóth E, Juhász I, Park JW, Isola J, Vereb G, Szöllosi J.

Cancer Lett. 2008 Feb 18;260(1-2):198-208. Epub 2007 Dec 21.

PMID:
18096313
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk